Cytek Biosciences (CTKB) director converts 6,107 RSUs to common stock
Cytek Biosciences director Richard Chin converted 6,107 Restricted Stock Units (RSUs) into an equal number of common stock shares on May 18, 2026, at a price of $0.00 per share. Following this transaction, Chin directly holds 22,392 common stock shares and 50,897 RSUs. The RSU award vests in multiple tranches through August 18, 2026.
Cytek Biosciences (CTKB) director adds 1,454 shares through RSU vesting
Cytek Biosciences director Michael Holder acquired 1,454 shares of common stock on May 18, 2026, through the exercise and conversion of restricted stock units (RSUs). This transaction was part of a routine equity compensation event and not an open-market purchase. Following this, Holder directly holds 16,721 common shares and 9,457 RSUs which will vest in tranches until August 2025.
Cytek Biosciences (CTKB) SVP nets shares after RSU vesting and tax withholding
Cytek Biosciences SVP Philippe Busque exercised awards for 10,464 shares of common stock from vested restricted stock units on May 18, 2026. To cover tax withholding, 2,685 shares were surrendered back to the company at $3.55 per share. Following these transactions, Busque directly holds 36,448 shares of Cytek Biosciences common stock and 5,641 unvested restricted stock units.
Cytek Biosciences (CTKB) CLO gains shares after RSU vesting
Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported the exercise of 24,295 Restricted Stock Units (RSUs) into common shares on May 18, 2026. A total of 8,719 shares were withheld at $3.55 per share to cover tax obligations, which is a routine compensation-related transaction and not an open-market sale. After these transactions, Barnett directly holds 136,009 common shares and retains 12,280 RSUs.
Cytek Biosciences (CTKB) CEO reports RSU vesting and tax share withholding
Cytek Biosciences' CEO, Wenbin Jiang, reported the vesting of Restricted Stock Units (RSUs) on May 18, 2026. He acquired 80,062 shares of common stock through RSU exercise and had 25,542 shares withheld for tax obligations at $3.55 per share. These transactions were compensation mechanics, not open-market sales, and Jiang continues to hold a significant stake in the company with over 5.43 million shares and remaining RSUs.
Cytek (CTKB) CFO nets shares from RSU vesting, surrenders stock for taxes
Cytek Biosciences CFO William D. McCombe recently received 25,719 shares of common stock from the vesting of Restricted Stock Units (RSUs) and subsequently surrendered 9,229 shares at $3.55 each to cover tax obligations. After these transactions, McCombe directly holds 98,739 shares of Cytek common stock. The event represents a routine equity compensation activity rather than open-market trading.
Cytek Biosciences invites researchers to webinar unveiling novel approach to sterilizing immunity for CDI
Cytek Biosciences is hosting a webinar to present a new method for achieving sterilizing immunity against Clostridioides difficile infection (CDI). This event is targeted at researchers focusing on vaccine development and translational immunology. The company aims to provide valuable insights to combat CDI, a significant health concern.
CTKB: Millennium-related filers report 6.1% and 5.4% stakes (May 15, 2026)
An amended Schedule 13G/A for Cytek Biosciences, Inc. (CTKB) indicates that Millennium-related entities, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, hold passive stakes of 5.4% and 6.1% in the company. The filing, dated May 15, 2026, details shared voting and dispositive power over 6,974,492 and 7,872,900 shares, respectively, and includes a Joint Filing Agreement formalizing their coordinated disclosure. This amendment clarifies group ownership and affirms that beneficial ownership is qualified by control relationships with Millennium-related managers.
Stephens cuts Cytek Biosciences stock price target on elevated costs By Investing.com
Stephens has cut its price target for Cytek Biosciences (NASDAQ: CTKB) to $4.75 from $5.50, while maintaining an Overweight rating. This decision follows Cytek's first-quarter fiscal 2026 revenue of $44.1 million, which was in line with estimates, but operating expenses remained elevated, leading to an EBITDA miss. Despite the price target reduction, Stephens noted the stock's valuation and potential acquisition interest as reasons to keep the Overweight rating, with InvestingPro suggesting the stock is currently undervalued.
Morgan Stanley Cuts Price Target on Cytek Biosciences to $5.50 From $6, Keeps Equalweight Rating
Morgan Stanley has lowered its price target for Cytek Biosciences (CTKB) to $5.50 from $6, while reiterating an "Equalweight" rating on the stock. This adjustment was reported on May 12, 2026, by MT Newswires. The article also provides recent news about Cytek Biosciences, including its Q1 2026 earnings call and revenue guidance.
Cytek Biosciences, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:CTKB) 2026-05-11
Cytek Biosciences, Inc. (CTKB) released its Q1 2026 earnings, reporting an EPS of -$0.10, missing estimates by $0.02, and revenue of $44.14M, a 6.46% year-over-year increase but still missing estimates by $165.00K. This article provides access to the slide deck published in conjunction with their earnings call.
Cytek Biosciences Balances Growth Momentum With Cost Pressures
Cytek Biosciences (CTKB) reported Q1 2026 earnings, showcasing solid revenue growth fueled by a strong U.S. market rebound and increasing recurring revenue, though it also faced margin pressure and a wider net loss. The company reaffirmed its full-year revenue guidance and expects adjusted EBITDA to improve quarterly, aiming for sustainable profitability despite facing higher legal and operating costs, regional disruptions, and foreign exchange impacts. Investors are watching whether the growth in recurring revenue and the U.S. market can offset these short-term profitability challenges.
Cytek Biosciences (CTKB) Margin Worsening With Q4 Loss Challenges Bullish Narratives
Cytek Biosciences (CTKB) reported a Q4 2025 revenue of US$62.1 million but recorded a basic EPS loss of US$0.34, significantly widening its annual loss to US$66.5 million. This financial performance raises concerns about margin pressure and the company's path to profitability, challenging previous bullish narratives, despite its current valuation being below industry averages. Investors are advised to consider the trade-off between growth, losses, and valuation.
Cytek Biosciences, Inc. - Common Stock (Nasdaq:CTKB) Stock Quote
This page provides a stock quote for Cytek Biosciences, Inc. (CTKB) on Nasdaq, showing its current price, intraday and 52-week ranges, trading volume, and market capitalization. It also lists recent news, earnings call transcripts, and performance data for the stock, indicating key company milestones and financial announcements. The article concludes with frequently asked questions about CTKB's public trading status and current stock details.
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences, Inc. (CTKB) reported a Q1 loss of $0.12 per share, exceeding the Zacks Consensus Estimate of a $0.08 loss, and revenues of $44.14 million, beating estimates by 0.59%. Despite underperforming the market year-to-date, the company's future stock movement will largely depend on management's commentary during the earnings call and evolving earnings expectations, currently holding a Zacks Rank #3 (Hold). Investors are also advised to consider the industry's outlook, with the Medical - Biomedical and Genetics industry currently in the bottom 40% of Zacks-ranked industries.
Cytek Biosciences, Inc. (CTKB) reports Q1 loss, beats revenue estimates
Cytek Biosciences, Inc. (CTKB) reported a Q1 loss per share that was narrower than anticipated, coming in at -$0.04 compared to analyst expectations of -$0.08. The company also surpassed revenue estimates, posting $36.42 million against a projected $35.08 million. This financial performance led to a slight increase in its share price during after-hours trading.
$44.1M quarter for Cytek Biosciences (NASDAQ: CTKB) as losses widen
Cytek Biosciences (NASDAQ: CTKB) reported Q1 2026 revenue of $44.1 million, a 6% increase year-over-year, driven by growth in both product and service sales. Despite the revenue growth, the company's net loss widened to $18.9 million from $11.4 million in the prior-year quarter, primarily due to increased operating expenses, particularly general and administrative costs. As of March 31, 2026, Cytek Biosciences maintained a strong liquidity position with $65.7 million in cash and cash equivalents and $196.6 million in marketable securities.
Cytek Biosciences, Inc. 1Q 2026: Revenue $44.14M, EPS ($0.15) — 10-Q Summary
Cytek Biosciences, Inc. reported its first-quarter 2026 financial results, with revenue increasing by 6.5% to $44.14 million from $41.46 million in the prior year. Despite revenue growth, the company recorded a net loss of $18.87 million and a diluted loss per share of ($0.15). The revenue growth was primarily driven by a 15% rise in service revenue and a 2% increase in product revenue, supported by an expanding installed base and strategic investments in R&D and commercial hiring.
Cytek adds 125 instruments as service revenue jumps 15%
Cytek Biosciences reported a 6% year-over-year increase in Q1 2026 revenue to $44.1 million, with service revenue jumping 15% to $15.4 million. The company expanded its installed base by 125 units, bringing the total to 3,789 instruments, and reaffirmed its full-year 2026 revenue guidance of $205M–$212M despite widening net losses and increased operating expenses. The stock, however, saw a 14.40% decline following the news.
Wider loss as Cytek Biosciences (Nasdaq: CTKB) grows Q1 2026 sales
Cytek Biosciences reported mixed Q1 2026 results, with total revenue increasing 6% year-over-year to $44.1 million, driven by strong U.S. instrument performance and growing service and reagent revenue. However, the company's net loss widened to $18.9 million, and adjusted EBITDA loss rose to $9.1 million, primarily due to a 43% surge in general and administrative expenses. Despite the increased losses, Cytek reaffirmed its 2026 revenue guidance of $205 million to $212 million, representing 2% to 5% growth over 2025, and maintained a solid liquidity position with $262.2 million in cash and marketable securities.
Cytek Biosciences Reports First Quarter 2026 Financial Results
Cytek Biosciences reported a 6% increase in total revenue to $44.1 million for Q1 2026 compared to Q1 2025, driven by strong U.S. performance and growth in service and reagent revenue. Recurring revenue now represents 35% of total revenue on a trailing-12-month basis, and the company added 125 instruments to its installed base. Despite global challenges, the company reaffirmed its 2026 revenue guidance of $205 million to $212 million.
Cmdorganization Launches Ransomware Attack on Cytek Biosciences
The ransomware group Cmdorganization has claimed responsibility for a cyberattack on Cytek Biosciences, a US-based biotechnology firm. The attackers allege they exfiltrated 7.36 TB of sensitive data and threaten to leak it if their demands are not met. DeXpose, a cybersecurity firm, reported the incident and provided recommendations for organizations to mitigate ransomware risks and enhance their security posture.
Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday
Cytek Biosciences (CTKB) is scheduled to announce its Q1 2026 earnings after market close on Thursday, May 7th, with analysts expecting an EPS of ($0.07) and revenue of $43.95 million. The company missed EPS estimates in the prior quarter but beat on revenue, and currently holds an average analyst rating of "Hold" with a target price of $5.38. Institutional investors hold a significant portion of the stock, which has seen considerable activity in recent quarters.
New Cytek Biosciences kit aims to boost high-resolution T cell analysis
Cytek Biosciences has released the Cytek cFluor 21-Color Human T-Cell kit, an optimized solution for high-resolution T cell profiling. This new kit is designed to streamline and improve the accuracy of T cell analysis for researchers and immunologists. It expands Cytek's offerings in flow cytometry tools and reduces resource-intensive workflows in laboratories.
Cytek Biosciences (NASDAQ: CTKB) details 2026 votes on board, pay and auditor
Cytek Biosciences (NASDAQ: CTKB) has released details for its 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026. Shareholders will vote on the election of three Class II directors, a non-binding advisory resolution on 2025 executive compensation, and the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The proxy statement also provides comprehensive information on executive compensation, director independence, and corporate governance practices, while reporting on the successful remediation of material weaknesses in internal control over financial reporting as of December 31, 2025.
Attachment
Cytek Biosciences has been recognized as the "Overall BioTech Company of the Year" in the fourth annual BioTech Breakthrough Awards. The company is lauded for making flow cytometry more accessible through its patented Full Spectrum Profiling™ (FSP™) technology, enabling broader scientific discoveries and innovation. This award highlights Cytek's impact on equipping scientists with advanced tools for research.
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Cytek Biosciences announced it will release its first quarter 2026 financial results after market close on Thursday, May 7, 2026. The company will also host a conference call and webcast on the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results and business outlook.
Cytek Biosciences (NasdaqGS:CTKB) Stock Forecast & Analyst Predictions
Cytek Biosciences (CTKB) is forecasted to grow earnings by 41.6% and revenue by 6.6% per annum, but is expected to remain unprofitable for the next three years. Analyst price targets have seen fluctuations, with recent increases due to improving sentiment in the diagnostic tools sector, clearer multi-year guidance, and European expansion initiatives. However, the stock has experienced volatility and insider selling, while its share price has underperformed earnings growth over the past three years.
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Cytek Biosciences, Inc. announced it will report its first quarter 2026 financial results after market close on Thursday, May 7, 2026. A conference call and webcast will follow at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss these results, business developments, and the company's outlook. The webcast will be available on the "Investors" section of their website.
Cytek Biosciences sets May 7 webcast for Q1 2026 results
Cytek Biosciences (Nasdaq: CTKB) will report its first quarter 2026 financial results after market close on Thursday, May 7, 2026. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, business developments, and outlook. Investors can access the live audio on the company's website.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Recommendation of "Hold" from Analysts
Cytek Biosciences, Inc. (NASDAQ:CTKB) has received an average "Hold" recommendation from six analysts, with a one-year average price target of $5.38. The company missed Q4 EPS estimates but exceeded revenue expectations, reporting a negative net margin. Institutional investors hold a significant stake in CTKB.
CTKB: Share Repurchases And 2026 Guidance Will Support Future Upside Potential
Cytek Biosciences (CTKB) recently completed a share repurchase program, buying back over 3.2 million shares for $15.3 million. The company also initiated 2026 revenue guidance between $205 million and $212 million, representing 2% to 5% growth over 2025. Analysts have maintained their $6.00 price target for CTKB, with minor adjustments to valuation inputs supporting the current valuation.
Attendees at ImmunologyAAI 109th meeting explore Cytek Biosciences new technology offerings
Cytek Biosciences is showcasing its latest flow cytometry solutions at the 109th annual meeting of the American Association of Immunologists (#IMMUNOLOGY2026). Attendees are invited to visit booth 911 to learn more about their advancements. This comes after Cytek Biosciences recently introduced a guide for optimizing drop charge settings for its Aurora CS system and launched the cFluor 21-Color Human T-Cell kit for enhanced immunoprofiling.
249,812 Shares in Cytek Biosciences, Inc. $CTKB Purchased by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL has acquired a new position in Cytek Biosciences (NASDAQ:CTKB), purchasing 249,812 shares valued at approximately $867,000. Other institutional investors like Topline Capital Management LLC and Royce & Associates LP also significantly increased their stakes in the company, bringing total institutional ownership to about 69.46%. Despite missing EPS estimates, Cytek Biosciences beat revenue expectations and holds a consensus "Hold" rating from analysts with a price target of $5.38.
Cytek Biosciences (CTKB) Inspiring Confidence With Aurora CS System Updates
Cytek Biosciences Inc. (NASDAQ:CTKB) has released updates to its Aurora CS system, including a new guide to simplify drop charge configurations for smaller samples and a Horseradish Peroxidase assay. The company also announced a 2026 revenue guidance of $205 million to $212 million, anticipating growth driven by an improved economic environment and increased instrument installations. Despite macroeconomic uncertainties, CTKB aims to enhance workflow reliability and accuracy for researchers.
Cytek Biosciences unveils 21-color T-cell kit to boost immunoprofiling workflows
Cytek Biosciences has launched its new Cytek cFluor 21-Color Human T-Cell kit, designed to enhance immunoprofiling workflows. This pre-optimized panel allows for high-resolution T cell profiling and provides a scalable platform for researchers in flow cytometry and immunology. The kit aims to support more detailed immune system analyses and T cell population understanding for both scientific and clinical applications.
Millennium Group reports 6.64M shares in Cytek Biosciences (CTKB)
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported shared beneficial ownership of 6,638,827 shares, or 5.2% of Cytek Biosciences (CTKB) Common Stock, as detailed in a Schedule 13G filing. This filing indicates a passive investment intent, not active control, and was executed through a joint filing agreement dated April 8, 2026. The shares are held by entities under the voting control and investment discretion of the reporting managers.
Cytek Biosciences streamlines drop charge optimization for small sample workflows
Cytek Biosciences has released a new guide to optimize drop charge settings for small sample workflows on its Aurora CS system, leveraging the Horseradish Peroxidase assay for enhanced precision. This initiative aims to assist laboratory professionals working with minimal sample volumes. This follows the company's recent expansion, including the successful first year of its Singapore facility, reinforcing its commitment to supporting global biotechnology operations.
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) reported a Q3 non-GAAP diluted loss of $0.02 per share, which is narrower than the Zacks Consensus Estimate of a $0.05 loss. The company's revenue for the quarter was $42.22 million, surpassing the consensus estimate by 0.52%. Despite the revenue beat, Cytek Biosciences has consistently fallen short of EPS estimates in the past four quarters.
Tudor Investment Corp ET AL Invests $867,000 in Cytek Biosciences, Inc. $CTKB
Tudor Investment Corp ET AL has initiated a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB), purchasing 249,812 shares valued at approximately $867,000, now owning 0.20% of the company. Institutional investors collectively hold 69.46% of the stock. Analyst sentiment is mixed with an average "Hold" rating and a target price of $5.38, while the company recently reported a revenue beat but an EPS miss for its latest quarter.
Cytek Biosciences, Inc. (CTKB) Stock Forecasts
The article provides a generic layout for a financial news page, specifically mentioning "Cytek Biosciences, Inc. (CTKB) Stock Forecasts" in its title. However, the content body primarily consists of navigation links, section titles, and various financial and lifestyle categories without any actual article text, stock forecasts, or company-specific information. It appears to be a stub or an error page rather than a complete article.
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Consensus Recommendation of "Hold" from Brokerages
Cytek Biosciences (NASDAQ:CTKB) has received a consensus "Hold" rating from six brokerages, with an average one-year target price of $5.38. The company recently reported a quarterly loss, missing EPS estimates, though revenue exceeded expectations. Despite institutional inflows, Cytek remains unprofitable with negative net margin and return on equity.
Vanguard realignment leaves Cytek (NASDAQ: CTKB) ownership at 0 after amendment
The Vanguard Group has reported 0 shares beneficially owned in Cytek Biosciences Inc. (NASDAQ: CTKB) in an amended Schedule 13G/A filing, representing 0% of the class. This change follows an internal realignment on January 12, 2026, where certain Vanguard subsidiaries or business divisions began reporting separately. As a result, Vanguard no longer claims beneficial ownership of securities held by these independent entities, indicating a neutral impact and sentiment on Cytek's stock.
CTKB: Sector Recovery And 2026 Guidance Will Support Upside Potential
Analysts have increased the target price for Cytek Biosciences (CTKB) to $5, citing improving sentiment in diagnostic tools and the company's clear multi-year growth framework. Bullish analysts see the updated 2026 guidance as a crucial catalyst for reassessing revenue projections, while bearish outlooks emphasize the reliance on this guidance and ongoing execution risks. The company recently completed a share repurchase program and provided revenue guidance for 2025 and 2026.
Cytek Biosciences outlines $205M–$212M 2026 revenue target amid record Q4 and growth in recurring revenue
Cytek Biosciences has projected a revenue target of $205 million to $212 million for 2026, driven by record fourth-quarter performance and an increase in recurring revenue. The company's growth strategy centers on expanding its product portfolio and market reach, particularly in the flow cytometry sector. This optimistic outlook reflects strong past performance and future expansion plans.
CTKB Stock News Today | Earnings, Events & Price Alerts
This page provides a comprehensive overview of news and events related to CTKB stock (Cytek Biosciences). It highlights recent earnings reports, including record Q4 2025 revenue and a 2025 revenue projection of $201 million, and an analyst's initiation of coverage with an "Equal Weight" rating. The platform aims to offer insights for investors monitoring CTKB.
Cytek Biosciences (CTKB) director converts 6,107 RSUs into common stock
Cytek Biosciences director Richard Chin converted 6,107 Restricted Stock Units (RSUs) into common stock on March 10, 2026, at no exercise price. Following this transaction, Chin directly holds 16,285 shares of common stock and retains 57,004 RSUs. These RSUs represent a contingent right to receive additional shares, vesting on a multi-date schedule.
Cytek Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Cytek Biosciences Inc (CTKB) reported an adjusted loss of 4 cents per share for the quarter ended June 30, beating analysts' mean expectation of a 7-cent loss. Revenue for the quarter fell 2.2% to $45.60 million, missing the expected $46.34 million. Analysts currently rate the stock as "buy" with a median 12-month price target of $5.50.
Topline Capital Management LLC Has $24.10 Million Position in Cytek Biosciences, Inc. $CTKB
Topline Capital Management LLC has significantly increased its stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 32.7%, bringing its total holding to 6,944,280 shares valued at approximately $24.10 million, making CTKB its ninth-largest position. Other institutional investors like Wellington Management Group and Arrowstreet Capital also adjusted their holdings, contributing to a high institutional ownership of 69.46%. Despite missing EPS estimates in its last quarterly report, Cytek Biosciences beat revenue expectations and currently holds an average analyst rating of "Hold" with a $5.50 price target.
Cytek Biosciences (CTKB) CEO awarded options, RSUs and surrenders shares for taxes
Cytek Biosciences President and CEO Wenbin Jiang reported significant equity compensation, including stock options for 485,545 shares and 915,407 restricted stock units (RSUs), both vesting over four years. He also surrendered shares to cover tax obligations arising from previously vested RSUs. Following these transactions, Jiang directly owned 5,422,683 shares of common stock.
